Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Mar 2;9(3):354.
doi: 10.1038/s41419-018-0386-3.

Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease

Guilherme S Mazzini  1   2 , Jad Khoraki  3 , Matthew G Browning  3 , Guilherme M Campos  3
Affiliations
Comment

Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease

Guilherme S Mazzini et al. Cell Death Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Comment on

References

    1. NCD-RisC. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387:1377–1396. doi: 10.1016/S0140-6736(16)30054-X. - DOI - PMC - PubMed
    1. Tanaka N, et al. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142–157. doi: 10.1016/j.pharmthera.2017.05.011. - DOI - PMC - PubMed
    1. Rodrigues PM, et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis. 2017;8:e2748. doi: 10.1038/cddis.2017.172. - DOI - PMC - PubMed
    1. Cheung O, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008;48:1810–1820. doi: 10.1002/hep.22569. - DOI - PMC - PubMed
    1. Loyer X, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARalpha expression. Gut. 2016;65:1882–1894. doi: 10.1136/gutjnl-2014-308883. - DOI - PMC - PubMed

Publication types